

- 9 **Seccareccia F**, Zuccaro P, Pacifici R, *et al*. Serum cotinine as a marker of environmental tobacco smoke exposure in epidemiological studies: the experience of the MATISS project. *Eur J Epidemiol* 2003;**18**:487–92.
- 10 **Kuss O**. How to use SAS® for logistic regression with correlated data. *Proceedings of the 27th Annual SAS® Users Group International Conference (SUGI 27)*, Orlando, Florida. SAS Institute Inc 2002: 261–327, <http://www2.sas.com/proceedings/sugi27/p261-27.pdf> (accessed 30 Sep 2006).
- 11 **Lancaster T**, Silagy C, Fowler G. Training health professionals in smoking cessation. *Cochrane Database Syst Rev* 2000;**3**:CD000214.
- 12 **Anderson P**, Jané-Llopis E. How can we increase the involvement of primary health care in the treatment of tobacco dependence? A meta-analysis. *Addiction* 2004;**98**:299–312.
- 13 **Coleman T**, Wynn AT, Barrett S, *et al*. Intervention study to evaluate pilot health promotion payment aimed at increasing general practitioners' antismoking advice to smokers. *BMJ* 2001;**323**:435–6.
- 14 **Coleman T**, Wynn AT, Stevenson K, *et al*. Qualitative study of pilot payment aimed at increasing general practitioners' antismoking advice to smokers. *BMJ* 2001;**323**:1–5.
- 15 **Silagy C**, Lancaster T, Stead L, *et al*. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev* 2004;**3**:CD000146.
- 16 **Hughes J**, Stead L, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2004;**4**:CD000031.
- 17 **Krause L**, Augustin R. Population survey on the consumption of psychoactive substances in the German adult population 2000. (In German.) *Sucht* 2001;**47**(Suppl 1):3–86.
- 18 **Hammond D**, McDonald PW, Fong GT, *et al*. Do smokers know how to quit? Knowledge and perceived effectiveness of cessation assistance as predictors of cessation behaviour. *Addiction* 2004;**99**:1042–8.
- 19 **Kaper J**, Wagena EJ, Severens JL, *et al*. Healthcare financing systems for increasing the use of tobacco dependence treatment. *Cochrane Database Syst Rev* 2005;**1**:CD004305.
- 20 **Curry SJ**, Grothaus LC, McAfee T, *et al*. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. *N Engl J Med* 1998;**339**:673–9.
- 21 **Schauffler HH**, McMenamin S, Olson K, *et al*. Variation in treatment benefits influencing smoking cessation: results of a randomised controlled trial. *Tob Control* 2001;**20**:175–80.
- 22 **McEwen A**, West R, Owen L. GP prescribing of nicotine replacement and bupropion to aid smoking cessation in England and Wales. *Addiction* 2004;**99**:1470–4.
- 23 **West R**, Hajek P, Stead L, *et al*. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction* 2005;**100**:299–303.
- 24 **Hughes JR**, Keely JP, Niaura RS, *et al*. Measures of abstinence in clinical trials: issues and recommendations. *Nicotine Tob Res* 2003;**5**:13–25.
- 25 **Senore C**, Battista RN, Ponti A, *et al*. Comparing participants and nonparticipants in a smoking cessation trial: selection factors associated with general practitioner recruitment activity. *J Clin Epidemiol* 1999;**52**:83–9.
- 26 **John U**, Meyer C, Rumpf HJ, *et al*. Relation among stage of change, demographic characteristics, smoking history, and nicotine dependence in an adult German population. *Prev Med* 2003;**37**:368–74.

The Lighter Side



Drew Sheneman. © Tribune Media Services, Inc. All Rights Reserved. Reprinted with permission.